Evidence map›Paper›PMID 36605468›Full record

ArticleEuropean journal of breast health2023

Genetic, Surgical and Oncological Approach to Breast Cancer, with

Aslı Subaşıoğlu, Zeynep Gülsüm Güç, Emine Özlem Gür, Mustafa Agah Tekindal, Murat Kemal Atahan

Open access · diamondAbstract read
In one paragraph

Article in European journal of breast health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.5field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 2 countries.

Aslı SubaşıoğluDepartment of Medical Genetics, İzmir Katip Çelebi University Faculty of Medicine, İzmir, Turkey.ORCID https://orcid.org/0000-0001-9011-6290
Zeynep Gülsüm GüçDepartment of Medical Oncology, İzmir Katip Çelebi University Faculty of Medicine, İzmir, Turkey.ORCID https://orcid.org/0000-0001-8960-2208
Emine Özlem GürDepartment of General Surgery, İzmir Katip Çelebi University Faculty of Medicine, İzmir, Turkey.ORCID https://orcid.org/0000-0003-2749-2220
Mustafa Agah TekindalDepartment of Biostatistics, İzmir Katip Çelebi University Faculty of Medicine, İzmir, Turkey.ORCID https://orcid.org/0000-0002-4060-7048
Murat Kemal AtahanDepartment of General Surgery, İzmir Katip Çelebi University Faculty of Medicine, İzmir, Turkey.ORCID https://orcid.org/0000-0002-0096-8789
Izmir Kâtip Çelebi University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: The aim of this study was to determine the frequency of germline variants in Materials and Methods: Medical history, and cancer diagnosis information for 195 independent probands with operated breast cancer were collected from requisition forms and medical records. The exonic regions and exon-intron junctions in Results: Gene variants (pathogenic, likely pathogenic and variants of unknown significance) were detected in 53 (27.2%). Detailed information about the patients (age of diagnosis, family history, gender), cancer stage, tumour characteristics (ER, PR, human epidermal growth factor receptor 2 status) and all information related to the detected variants (gene, location, nucleotide and amino acid change, exon number, impact, mutation classification, dbSNP number and HGMD variant class) were assessed. In total, 58 mutations were identified including 14 novel, previously unreported variants. Conclusion: Molecular characterization and identification of mutations have important implications for predictive, preventive, and personalized medicine, including genetic counseling and development of specific treatment protocols. We emphasize variants of unknown significance (VUS) as the clinical significance of VUS changes over time and variant classification is important for clinical molecular genetic testing and clinical guidance. This study may provide new insights into risk assessment for variants in

Indexed as

BRCA1/2breast cancerCDH1/PALB2genetic testingTP53/PTEN

Identifiers

PMID36605468
PMCPMC9806937
OpenAlexW4313258524

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.